This document is an investor presentation on the financial results of Apollo Hospitals Enterprise Limited for the three months ended June 30, 2026 (Q1 FY27), submitted in compliance with SEBI Listing Regulations. The presentation was uploaded to the company's website (www.apollohospitals.com) on August 12, 2026.

The presentation provides a comprehensive overview of the company's Q1 FY27 financial and operational performance across all business segments.

Management Participants: The document is signed by S.M. Krishnan, Sr. Vice President - Finance and Company Secretary.

Compliance Language: The document includes standard disclaimer language stating that it contains forward-looking statements, does not constitute an offer of securities, and that no unpublished price sensitive information (UPSI) is being shared.

Financial Highlights Disclosed:

  • Consolidated Total Revenues: ₹70,435 million in Q1 FY27 (21% YoY growth from ₹58,421 million)
  • Consolidated EBITDA: ₹10,920 million (28% YoY growth from ₹8,519 million)
  • Consolidated PAT (Reported): ₹5,805 million (34% YoY growth from ₹4,328 million)
  • Healthcare Services Revenue: ₹35,670 million (22% YoY growth)
  • Healthcare Services EBITDA Margin: 24.2% (30 bps improvement)
  • Apollo Health and Lifestyle Ltd (AHLL) Revenue: ₹4,995 million (15% YoY growth)
  • Apollo HealthCo Revenue: ₹24,718 million (20% YoY growth)
  • Apollo HealthCo PAT: ₹1,017 million (78% YoY growth)
  • Digital Platform GMV: ₹5,351 million (23% YoY growth)

Operational Metrics:

  • Operating Beds: 8,352 (4% increase YoY)
  • Occupancy: 70% (vs 65% YoY)
  • IP Discharges: 171,662 (13% increase YoY)
  • Average Revenue Per Inpatient: ₹186,630 (8% increase YoY)

Expansion Plans:

  • Commissioned 5 new hospitals (~1,000 census beds) in last two quarters
  • Total project cost of ~₹11,150 crores with balance to be spent of ~₹7,500 crores
  • 380 beds already operationalized, remaining 620 beds to be activated over 12-18 months

Strategic Initiatives:

  • Apollo Health & Lifestyle's Mother & Child and Fertility Businesses valued at ₹1,550 Crores through combination with Cloudnine (subject to CCI approval)
  • Composite scheme approved for restructuring Apollo HealthCo to create an 'Indian Owned and Controlled Company' (IOCC)
  • Apollo 24|7 platform has 49M+ registered users and ~8 lakh daily active users

Additional Notes Section

The document includes the full investor presentation with detailed financial and operational data across all business segments (Healthcare Services, Retail Health, Diagnostics, Pharmacy, Digital Health).

Financial data was extensively disclosed in the announcement, including segment-wise breakdowns of revenue, EBITDA, EBIT, PBT, and PAT.

The presentation contains forward-looking statements about future performance and expansion plans, with appropriate disclaimers about the inherent risks and uncertainties.